Serum Metrnl levels were reduced in individuals with overweight or obesity and were independently associated with adverse lipid profile, suggesting that modifying circulating Metrnl levels may serve as a potential therapeutic target for atherogenic dyslipidemia. This evidence concerns the gene METRNL and obesity due to melanocortin 4 receptor deficiency.